Thyroid carcinoma: molecular pathways and therapeutic targets - Wikidata - wikimedia - TriplyDB

Thyroid carcinoma: molecular pathways and therapeutic targets

Thyroid carcinoma: molecular pathways and therapeutic targets

http://www.wikidata.org/entity/Q37147768

about

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene Molecular Targeted Therapies of Aggressive Thyroid Cancer Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?Current status and future perspectives in differentiated thyroid cancer RAS mutations in thyroid cancer Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer Accurate diagnosis of thyroid follicular lesions from nuclear morphology using supervised learning.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.Diagnosis and reporting of follicular-patterned thyroid lesions by fine needle aspiration TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia Current concepts and future directions in differentiated thyroid cancer.Metastatic phenotype is regulated by estrogen in thyroid cells.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma.DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.Poorly Differentiated Thyroid Carcinoma: 10-Year Experience in a Southeast Asian Population.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma.Multi-targeted approach in the treatment of thyroid cancer.Synchronous primary triple carcinoma of thyroid and kidney accompanied by solitary fibrous tumor of the kidney: a unique case report.Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns Evaluation of NDRG2 gene expression in primary papillary thyroid carcinoma and in metastases of this neoplasm to regional lymph nodes.DNA instability at chromosomal fragile sites in cancer Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma.Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid.Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report.Detection and classification of thyroid follicular lesions based on nuclear structure from histopathology images.High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphase FISH Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib Oncogenic gene fusions in epithelial carcinomas Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer Subclassification of the "grey zone" of thyroid cytology; a retrospective descriptive study with clinical, cytological, and histological correlation.

P2860

Q24598210-8A8C6975-A1FF-483A-8BFD-B98E26AD23AB Q26774734-ABFA9711-F86D-4BF2-9218-34C2730574DF Q26820880-C2F45C10-B2E8-4807-B195-2DD2192FA418 Q26821959-83806A89-C48D-43EF-BDB5-D3DF118780AE Q26828446-7102446C-DE8F-4360-AE30-30685879CA29 Q27024484-1FB72BAA-D0BE-48A1-BD54-9B924777E311 Q27026163-4F3F83C2-78D8-4DC1-92EB-CD6D79C50EF0 Q27851560-853E3CAB-567B-4019-A7FD-CD9911A6179F Q28084710-5C2EE682-7618-461F-8022-22191A2C42AA Q28476759-409D5895-C40B-457F-8A21-F17E6BB96227 Q30384499-C9D12ADE-EFBA-4A7C-AB90-C26A7640A0CE Q33569996-931BDDD5-FA1D-49C6-B957-505C9AEE560E Q33594818-35B8A1E1-34DE-46F7-88A3-5E887C8EAE2B Q33636784-E9FB57F5-584D-4B6C-8DF0-E93EFB280488 Q33677589-F7152E85-F47C-4C7E-A0F5-54E98818F4A8 Q33707854-F8FA45B0-809F-4A14-93D1-D12F54BCC06F Q33770769-5C240A54-41D0-4750-829E-E9671F09E304 Q33771043-BCF7C0DD-D376-465B-9844-50ED68509EA5 Q33792630-030743C0-810C-4F53-892F-53F8936E0E8D Q33889905-7F036324-0D93-4AC5-B1A6-17B5863BEA08 Q33914771-14F45D14-2917-43AC-A858-B77647290ECA Q33931406-0D1FA60D-DB80-47EF-BC88-52BF8236F991 Q33982413-8B543D4F-8D3A-45E7-B02E-B1D78DF536C1 Q34029238-6EFA26DF-DF2E-4DE7-BCFF-8D7F72C91615 Q34042241-80F89F6D-72C0-4B23-89D0-B2223A2903E4 Q34109756-9963EB99-0A5F-4FFD-8680-11A67A572AF6 Q34119294-97950BDB-7A52-42B5-BFCF-71EB70A24C44 Q34128093-BA590F25-9F01-4E79-9889-6529CB6B050F Q34152853-5362173A-4F81-45F4-8B6A-D55AA9CE267C Q34179794-CD9FD6F3-3160-4E47-99CF-2F1DA0B379DC Q34183230-4ADB2F40-731F-4B7A-B096-0692BA473E35 Q34298364-F4867225-995B-4D1E-BE60-9D397D98EFA0 Q34443680-5C67F5FA-3837-419D-ADC7-34196499AD77 Q34572289-3EDD4206-63C5-4296-910F-A09EB1E9D16A Q34711521-2EA6F3F2-AFFD-4FB3-8F26-1C271DCF22E4 Q34714310-18CCDF33-00F8-47B4-8B14-54A0D6512559 Q34929133-8BE91AD4-FDAE-46A0-895C-9E705216C129 Q34949690-28354E4B-51AA-4D16-92F2-2F3BBD1273BF Q34976419-9E7506D6-2166-43C2-B08D-5C7D6D5B7079 Q35098913-CBA4338F-AE63-4FDA-8A43-A1C63F52E1D8

P2860

Thyroid carcinoma: molecular pathways and therapeutic targets

http://www.wikidata.org/entity/Q37147768

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Thyroid carcinoma: molecular pathways and therapeutic targets

@en

Thyroid carcinoma: molecular pathways and therapeutic targets.

@nl

type

label

Thyroid carcinoma: molecular pathways and therapeutic targets

@en

Thyroid carcinoma: molecular pathways and therapeutic targets.

@nl

prefLabel

Thyroid carcinoma: molecular pathways and therapeutic targets

@en

Thyroid carcinoma: molecular pathways and therapeutic targets.

@nl

P1433

Q37147768-44F46A62-78F8-4FC5-B737-1BB50861107E

P1476

Q37147768-6B87DCD5-8FCB-4C92-A357-781D3AD48617

P2093

Q37147768-615CD1EC-00C8-4AB6-9D95-F3DF45C686B4

P2860

Q37147768-03DB60E6-61B6-4195-B6D6-95C392DE7E0A

Q37147768-04D340FD-C551-4C0E-9E44-EACBA0DA79BA

Q37147768-0602B857-84F5-4F09-B411-7FD05EB9A8E8

Q37147768-0A4C6672-6527-4964-8B44-FA6ABBB12AD5

Q37147768-1BF146F9-72F3-4729-AC96-99F5EEBF2A9A

Q37147768-2BC6CBF9-3312-4092-BD55-E3EC9399EB9F

Q37147768-2E8F405B-F976-4ABB-9AE4-B1BD6499B41E

Q37147768-32632C51-45B4-4767-B699-8D1C44444988

Q37147768-35A03BA6-D3DA-40C8-9F81-6308141D51EA

Q37147768-35A80B09-1E95-4CF1-A21D-18B9F1DBDB21

P2888

Q37147768-76D39C16-4968-4D81-81AB-0C205CB2BDE5

P304

Q37147768-769956DA-7DF5-4BE2-AB68-22A08653A9B5

P31

Q37147768-55CA641E-EA3D-47D3-9E1C-DC7D62B550E1

P356

Q37147768-157A9675-D9AA-43E5-BE8B-54D96C0EE714

P478

Q37147768-EBF136F8-C981-4BEC-B68D-EA6A8603E5AD

P577

Q37147768-94B9A48F-1E6C-47ED-8AF2-23A009ED4807

P5875

Q37147768-FD13D681-0A86-4819-947B-11497A354543

P698

Q37147768-21E27657-6BEE-47F8-9A8F-2565A1F30947

P932

Q37147768-50831DDE-1575-45BC-8D4D-D38E248E3205

P356

MODPATHOL.2008.10

P1433

Modern Pathology

P1476

Thyroid carcinoma: molecular pathways and therapeutic targets

@en

P2093

Yuri E Nikiforov

http://www.w3.org/2001/XMLSchema#string

P2860

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Targeting BRAF in thyroid cancer

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

RET/PTC rearrangement in thyroid tumors

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

BRAF mutation predicts sensitivity to MEK inhibition

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P2888

modpathol.2008.10

P304

S37-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2008.10

http://www.w3.org/2001/XMLSchema#string

P478

21 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5416076

http://www.w3.org/2001/XMLSchema#string

P698

18437172

http://www.w3.org/2001/XMLSchema#string

P932

2673022

http://www.w3.org/2001/XMLSchema#string